Technical Analysis for AVCTF - Avacta Group Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | 20.00% | |
| Narrow Range Bar | Range Contraction | 20.00% | |
| New 52 Week Closing Low | Bearish | 20.00% | |
| Narrow Range Bar | Range Contraction | 20.00% | |
| New 52 Week Low | Weakness | 20.00% | |
| Gapped Down | Weakness | 20.00% | |
| Narrow Range Bar | Range Contraction | -26.83% | |
| Gapped Up | Strength | -26.83% |
Get a Trading Assistant
Avacta Group Plc Description
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biopharmaceutical Life Sciences Stem Cells Autoimmune Diseases Alpha Stage Biopharmaceutical Immunotherapies Drug Development Cancer Therapies Novel Cancer Party Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.29 |
| 52 Week Low | 1.25 |
| Average Volume | 1,216 |
| 200-Day Moving Average | 0.0000 |
| 50-Day Moving Average | 0.0000 |
| 20-Day Moving Average | 0.0000 |
| 10-Day Moving Average | 1.8060 |
| Average True Range | 0.0000 |
| RSI (14) | 0.00 |
| ADX | 0.0 |
| +DI | 0.0000 |
| -DI | 0.0000 |
| Chandelier Exit (Long, 3 ATRs) | N/A |
| Chandelier Exit (Short, 3 ATRs) | N/A |
| Upper Bollinger Bands | 0.0000 |
| Lower Bollinger Band | 0.0000 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.0000 |
| MACD Line | -0.0252 |
| MACD Signal Line | -0.0050 |
| MACD Histogram | -0.0201 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.5000 | ||||
| Resistance 3 (R3) | 1.5000 | 1.5000 | 1.5000 | ||
| Resistance 2 (R2) | 1.5000 | 1.5000 | 1.5000 | 1.5000 | |
| Resistance 1 (R1) | 1.5000 | 1.5000 | 1.5000 | 1.5000 | 1.5000 |
| Pivot Point | 1.5000 | 1.5000 | 1.5000 | 1.5000 | 1.5000 |
| Support 1 (S1) | 1.5000 | 1.5000 | 1.5000 | 1.5000 | 1.5000 |
| Support 2 (S2) | 1.5000 | 1.5000 | 1.5000 | 1.5000 | |
| Support 3 (S3) | 1.5000 | 1.5000 | 1.5000 | ||
| Support 4 (S4) | 1.5000 |
